1. Home
  2. KPRX vs TOUR Comparison

KPRX vs TOUR Comparison

Compare KPRX & TOUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KPRX
  • TOUR
  • Stock Information
  • Founded
  • KPRX 1998
  • TOUR 2006
  • Country
  • KPRX United States
  • TOUR China
  • Employees
  • KPRX N/A
  • TOUR N/A
  • Industry
  • KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • TOUR Transportation Services
  • Sector
  • KPRX Health Care
  • TOUR Consumer Discretionary
  • Exchange
  • KPRX Nasdaq
  • TOUR Nasdaq
  • Market Cap
  • KPRX 8.3M
  • TOUR 101.0M
  • IPO Year
  • KPRX N/A
  • TOUR 2014
  • Fundamental
  • Price
  • KPRX $3.12
  • TOUR $0.95
  • Analyst Decision
  • KPRX Strong Buy
  • TOUR
  • Analyst Count
  • KPRX 1
  • TOUR 0
  • Target Price
  • KPRX $10.00
  • TOUR N/A
  • AVG Volume (30 Days)
  • KPRX 11.2K
  • TOUR 102.2K
  • Earning Date
  • KPRX 05-20-2025
  • TOUR 06-03-2025
  • Dividend Yield
  • KPRX N/A
  • TOUR 3.81%
  • EPS Growth
  • KPRX N/A
  • TOUR N/A
  • EPS
  • KPRX 0.87
  • TOUR 0.09
  • Revenue
  • KPRX $16,020,000.00
  • TOUR $70,367,853.00
  • Revenue This Year
  • KPRX N/A
  • TOUR $16.99
  • Revenue Next Year
  • KPRX N/A
  • TOUR $13.23
  • P/E Ratio
  • KPRX $3.68
  • TOUR $10.94
  • Revenue Growth
  • KPRX N/A
  • TOUR 16.40
  • 52 Week Low
  • KPRX $2.51
  • TOUR $0.71
  • 52 Week High
  • KPRX $5.55
  • TOUR $1.76
  • Technical
  • Relative Strength Index (RSI)
  • KPRX 50.24
  • TOUR 52.37
  • Support Level
  • KPRX $3.18
  • TOUR $0.90
  • Resistance Level
  • KPRX $3.48
  • TOUR $0.98
  • Average True Range (ATR)
  • KPRX 0.19
  • TOUR 0.04
  • MACD
  • KPRX 0.02
  • TOUR 0.01
  • Stochastic Oscillator
  • KPRX 45.39
  • TOUR 75.08

About KPRX Kiora Pharmaceuticals Inc.

Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.

About TOUR Tuniu Corporation

Tuniu Corp is an online leisure travel company. The company is engaged in the provision of travel-related services in the People's Republic of China. It offers a large selection of packaged tours, including organized tours and self-guided tours, as well as travel-related services for leisure travelers. The company's organized tours provide pre-arranged itineraries, transportation, accommodations, entertainment, meals, and tour guide services. Its self-guided tours consist of combinations of flights and hotel bookings and other optional add-ons. The company derives almost all of its revenue from PRC.

Share on Social Networks: